Moderna and BioNTech are getting all of the attention with their phase 3 clinical trials for lung cancer and melanoma.  But someone else is already further ahead.  French company Ose Immunotherapeutics has already done a phase...

Cancer vaccines are an area that anyone who is anyone is getting into, but it's a field  led largely by academics, not-for–profits, and specialist researchers. So this week we go back to basics - science that is. Australia may ...

In some ways, cancer vaccines are a history of hype and hope, over success. But that hasn't stopped people from trying. In 2024, biotech CEOs are hoping that this time, it's different. Research houses are predicting significant market g...

Cancer vaccines are a very niche section of cancer treatments. But two companies in Australia – the only two so far to go public with their work in this arena –are working on an even niche area within this. And one says their work is not a vacc...

Cancer vaccines started out as prevention. Think Gardasil for cervical and oral cancers caused by HPV, and the hepatitis B vaccine for liver cancer.But today the science has moved on, to therapy vaccines. Vaccines that take immune cells...

Drone-deliveries of radioactive medicines and diagnostics to Australia's far-flung towns. Radiopharmaceuticals matched with genetic information to tailor precisely the right dose and isotope to a person's cancer. Pan-cancer drugs that fix many ...

The rule of thumb in biotech is that it costs around $1 billion to bring a new therapy from lab to market. Protecting that investment is the patent system. But what if part of your product is not made by your contract manufacturer, but by the p...

Can Australia create a mine to lab to bedside production line for radiopharmaceutical medicine? It has the reactor, biotechs and the hospitals to do that last two, and even has a growing pool of expertise to run these. What it doesn...

The question we are dancing around in episode 3 of NUKED is whether locking down isotopes supply chains are really the only way to play the radiopharmaceutical game. We ask Clarity Pharmaceutical executive chair Alan Taylor and <...

In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem.  Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment sched...

The radiopharmaceuticals sector is on a knife point. The scope of what nuclear medicine can do is exploding. But the radioisotopes that biotechs need to make those therapies are in very, very short supply. Major clinical trials are hitting paus...

Wearable kidneys. Organs on a chip. Xenotransplantation. The future is here.But is that the future people in biotech are truly looking to? Because the future that Certa Therapeutics CEO Darren Kelly is looking to is much less 1980s sci-...

We may have led you on a bit in the first two episodes... kidney disease is still a big problem despite the massive shifts forward in treating it. There is a long way to go to bring medical sectors -- and governments -- along as well. ...

We speak to Dimerix CEO Dr Nina Webster about why investors are thrilled with her company, as it nears the midway point for its Phase III clinical trial for the rare disease focal segmental glomerulosclerosis (FSGS).And we talk to PYC T...

Kidney disease is a silent killer, with only 10% of all people knowing they have it before damage has been done. But in the last five years there's been a surge of work that's resulted in the FDA approving some blockbuster drugs in...

Life sciences more than anywhere else is the successful mashup of money and tech.  I'm Rachel Williamson and this is Phase III, a weekly podcast diving deep into Australian life sciences. In each of our short series, we investigate...